A Phase 2 Trial Testing ZP1848 in Patients With SBS
NCT02690025 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 18
Last updated 2017-06-21
Summary
A proof-of-concept, dose finding, controlled, single-center, randomized, double-blind, fixed dose phase 2 trial with ZP1848 in patients with Short Bowel Syndrome.
Conditions
- Short Bowel Syndrome
Interventions
- DRUG
-
ZP1848
Sponsors & Collaborators
-
Larix A/S
collaborator INDUSTRY - lead INDUSTRY
Principal Investigators
-
Gertrud Koefoed Rasmussen, MSc · Zealand Pharma A/S
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- QUADRUPLE
- Model
- CROSSOVER
Eligibility
- Min Age
- 18 Years
- Max Age
- 90 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2016-02-29
- Primary Completion
- 2017-05-31
- Completion
- 2017-05-31
Countries
- Denmark
Study Locations
More Related Trials
-
Safety, Pharmacokinetics, and Pharmacodynamics/Efficacy of SBC-103 in Mucopolysaccharidosis III, Type B (MPS IIIB)
NCT02324049 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Efficacy and Safety Evaluation of Glepaglutide in Treatment of Short Bowel Syndrome
NCT07228403 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE3
-
An Open-Label Study of Oral NNZ-2591 in Prader-Willi Syndrome (PWS-001)
NCT05879614 ·Status: WITHDRAWN ·Phase: PHASE2
-
A Open Label Extension Study for Subjects That Complete Study MP-101-CL-001
NCT02246816 ·Status: WITHDRAWN ·Phase: PHASE3
-
A 2-Part Study to Assess Efficacy, Safety and Tolerability of BMB-101 for the Treatment of Patients With Prader-Willi Syndrome.
NCT07266324 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Clinical Study of Cannabidiol in Children, Adolescents, and Young Adults With Fragile X Syndrome
NCT04977986 ·Status: COMPLETED ·Phase: PHASE3
-
A Open Label Study in Previously Studied, SBC-103 Treatment Naïve MPS IIIB Subjects to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics/Efficacy of SBC-103 Administered Intravenously
NCT02618512 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
An Open-Label Study of Oral NNZ-2591 in Phelan-McDermid Syndrome (PMS-001)
NCT05025241 ·Status: COMPLETED ·Phase: PHASE2
-
A Safety Study of NNZ-2566 in Patients With Fragile X Syndrome
NCT01894958 ·Status: COMPLETED ·Phase: PHASE2
-
Study of DNL126 in Pediatric Participants With Mucopolysaccharidosis Type IIIA (Sanfilippo Syndrome Type A)
NCT06181136 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Natural History Study to Characterise the Course of Disease Progression in Participants With Mucopolysaccharidosis Type IIIB
NCT02293408 ·Status: TERMINATED
-
A Study of Pitolisant in Participants With Prader-Willi Syndrome
NCT07219485 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE3
-
Pharmacokinetics and Safety of Givinostat in DMD Patients Ages From at Least 2 Years to Less Then 6 Years Old
NCT06769633 ·Status: RECRUITING ·Phase: PHASE2
-
Safety, Tolerability, Pharmacokinetics (PK), and Activity of ATYR1940 in Participants With Muscular Dystrophy - Study Extension
NCT02531217 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Safety Study of NNZ-2566 in Patients With Rett Syndrome
NCT01703533 ·Status: COMPLETED ·Phase: PHASE2
-
A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZYIL1 in Subjects With Cryopyrin Associated Periodic Syndromes (CAPS)
NCT05186051 ·Status: COMPLETED ·Phase: PHASE2
-
Open-Label Study of ZYN002 Administered as a Transdermal Gel to Children and Adolescents With 22q11.2 Deletion Syndrome (INSPIRE)
NCT05149898 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of NNZ-2591 in Pediatric Participants With Phelan-McDermid Syndrome
NCT07281079 ·Status: RECRUITING ·Phase: PHASE3
-
Evaluate Safety and Biological Activity of ATYR1940 in Participants With Early Onset Facioscapulohumeral Muscular Dystrophy
NCT02603562 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Efficacy and Safety Study of Protein C Concentrate in Subjects With Severe Congenital Protein C Deficiency
NCT00157118 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-318 in Subjects With MPS I
NCT02702115 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Evaluation of the Efficacy and Safety of VX-814 in Subjects With the PiZZ Genotype
NCT04167345 ·Status: TERMINATED ·Phase: PHASE2
-
Clinical Study Of caNNabidiol in childrEn and adolesCenTs With Fragile X (CONNECT-FX)
NCT03614663 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
An Open-Label Study of Oral NNZ-2591 in Pitt Hopkins Syndrome (PTHS-001)
NCT05025332 ·Status: COMPLETED ·Phase: PHASE2
-
An Open-Label Extension Trial to Assess the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride HCl) Oral Solution in Children and Young Adults With Dravet Syndrome
NCT02823145 ·Status: COMPLETED ·Phase: PHASE3